Kristin J. Moore

Kristin J. Moore

Auto-generated profile, based on publicly available information

Kristin J. Moore

Value and Evidence Solutions, Optum Life Sciences, Eden Prairie, MN, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2018 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
KVKristin J. Voltzke
Kristin J. Voltzke
YLYuan-Chin Amy Lee
Yuan-Chin Amy Lee
ZZZuo-Feng Zhang
Zuo-Feng Zhang
JZJose P. Zevallos
Jose P. Zevallos
GYGuo-Pei Yu
Guo-Pei Yu
AOAndrew F. Olshan
Andrew F. Olshan

30 June 2020 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
KMKristin J Moore
Kristin J Moore
SXSerena Xiong
Serena Xiong
MBManami Bhattacharya
Manami Bhattacharya
GBGabriela Bustamante
Gabriela Bustamante
CCCollin Calvert
Collin Calvert
Increasing diversity and inclusion among organizational membership has become a focus for many professional societies, including the Society for Epidemiologic Research (SER). In this issue of the Journal, DeVilbiss et al. (Am J Epidemiol. 2020:189(10):998–1010) assessed dimensions of diversity and inclusion within SER to provide baseline data for future evaluations of Society initiatives. In our response, we note that diversity in SER appears strong but there is lag with regard to inclusion. We also highlight some of the major weaknesses of this study that hinder efforts to accurately evaluate inclusion within SER. There is a need to more concretely define inclusion and think broadly about how measures of inclusion should be operationalized in future surveys. Additional limitations of the study include its limited generalizability to the wider SER membership and the lack of questions about barriers to inclusion in SER activities. We conclude with recommendations for SER and other professional societies based on prior literature evaluating successful diversity and inclusion efforts. We also propose a conceptual model to assist with operationalizing and directing future analyses of inclusion measures. It is essential that SER move beyond efforts around diversity to focus on measuring and enhancing inclusion.

14 June 2020 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
KMKristin J. Moore
Kristin J. Moore
AHAubrey K. Hubbard
Aubrey K. Hubbard
LWLindsay A. Williams
Lindsay A. Williams
LSLogan Garrett Spector
Logan Garrett Spector

10 March 2020 in Birth Defects Research
Verified
Journal Article
Closed access
PDF file
KMKristin J. Moore
Kristin J. Moore
SCSuzan L. Carmichael
Suzan L. Carmichael
NFNina E. Forestieri
Nina E. Forestieri
TDTania A. Desrosiers
Tania A. Desrosiers
RMRobert E. Meyer
Robert E. Meyer
TSThe National Birth Defects Prevention Study
The National Birth Defects Prevention Study

1 October 2025 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
Justin GatwoodJustin Gatwood
Justin Gatwood
YZYong Zhu
Yong Zhu
ASAndrea Steffens
Andrea Steffens
SGStephanie J Gallagher
Stephanie J Gallagher
MDMary C DuCharme
Mary C DuCharme
NSNikita Stempniewicz
Nikita Stempniewicz
Purpose: Cancer and immunosuppressive medications used for its treatment increase the risk for herpes zoster (HZ) among adults. This study described the incidence of HZ and its complications among United States (US) adults with specific solid tumors and hematological malignancies following initiation of immunosuppressive therapy. Patients and Methods: This retrospective cohort study used administrative claims data from October 2015 to December 2022 and included US adults with ≥ 1 immunosuppressive medication claim, ≥ 12 months continuous enrollment (baseline) prior to the first immunosuppressive medication claim, a cancer diagnosis, and no HZ diagnosis or vaccination in the baseline period. HZ incidence rates (IRs) were calculated as the number of new HZ cases per 1000 person-years at risk, stratified by cancer type and medication class. The proportions of patients with HZ-related complications such as postherpetic neuralgia, herpes zoster ophthalmicus, disseminated HZ, and HZ-related meningoencephalitis were described. A time-dependent Cox proportional hazards regression estimated adjusted hazard ratios, controlling for patient age, sex, race and ethnicity, comorbidities, prior healthcare utilization, insurance type, region, and baseline immunosuppressive medication use. Results: The overall IRs of new HZ cases in patients with a solid tumor or a hematological malignancy were 20.9 (95% confidence interval [CI]: 20.33‒21.52) and 31.1 (95% CI: 29.64‒32.52) per 1,000 person-years, respectively. HZ IR was highest in patients with non-Hodgkin lymphoma (35.4, 95% CI: 33.05‒37.77) or chronic lymphocytic leukemia (35.1, 95% CI: 31.24‒39.24). By medication class, the highest HZ IRs were associated with mycophenolic acid, azathioprine, and oral glucocorticoids. In adjusted analyses, patients were more likely to develop HZ during periods of immunosuppressive medication use versus periods without (adjusted hazards ratio [95% CI]: 3.2 [3.01‒3.39] for solid tumor, 3.2 [2.89‒3.57] for hematological malignancy). Conclusion: HZ incidence among US adults with solid tumors and hematological malignancies following immunosuppressive therapy initiation was high, reinforcing the need to prioritize HZ vaccination in these populations. Plain Language Summary: Why was the study done? Adults with cancer have a higher risk of developing herpes zoster (HZ) compared to the general population, due to both cancer and its treatments. The risk of HZ in adults by cancer type and medication class has not yet been comprehensively examined. What did the researchers do and find? This study estimated HZ incidence among United States adults with cancer following immunosuppressive therapy initiation. This study found that HZ incidence is particularly high in patients with solid tumors or hematological malignancies in the period following immunosuppressive medication initiation. Moreover, patients consistently on immunosuppressive therapy were more likely to develop HZ compared to patients with less consistent use of immunosuppressive medications. We identified mycophenolic acid, azathioprine, and oral glucocorticoids as medications associated with higher rates of HZ incidence. What do these results mean? The findings provide oncologists and hematologists with information about the risk of HZ in patients with different cancer types during periods of immunosuppressive medication use. This may also inform decision makers about the need for HZ vaccination in patients at increased risk for HZ due to both their health condition and treatment. Finally, this may provide guidance to providers by linking the need for HZ prevention with specific classes of medications, irrespective of their connection to cancer therapy.

1 June 2024 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
KKKristin Kahle-Wrobleski
Kristin Kahle-Wrobleski
BBBonnie Kh Bui
Bonnie Kh Bui
JFJennifer Friderici
Jennifer Friderici
KMKristin J Moore
Kristin J Moore
MCMaureen Carlyle
Maureen Carlyle
JWJohn Westfall
John Westfall
Purpose: Current guidelines recommend triple therapy maintenance inhalers for patients with recurrent exacerbations of chronic obstructive pulmonary disease (COPD); however, these maintenance therapies are underutilized. This study aimed to understand how physicians make COPD treatment decisions, and how combination maintenance therapies are utilized in a real-world setting. Patients and Methods: This exploratory, hypothesis-generating, non-interventional study used a cross-sectional online survey that was administered to a sample of practicing physicians in the United States. The survey included five fictitious vignettes detailing common symptoms experienced by patients with COPD. Survey questions included factors physicians consider in their decisions, and perceived barriers to prescribing treatments. Repeated measures multivariable analyses were conducted to evaluate how likely physicians were to switch to triple therapy versus no change to patient’s current maintenance therapy or change to another maintenance therapy. Results: In total, 200 physicians completed the survey. Cost of treatment and patient access to treatment were reported as the most common barriers physicians consider in their prescribing decisions. Physicians were more likely to switch a patient’s maintenance inhaler to triple therapy versus no change to maintenance inhaler if they considered the patient’s history of new symptoms, insurance status, and clinical guidelines in their decision. Physicians with more experience treating patients with COPD, and those who treat more patients with COPD per week, were more likely to switch to triple therapy versus no change to maintenance inhaler. Conclusion: This study demonstrates the complexity of factors that can influence physicians’ decisions when prescribing treatments for patients with COPD, including considerations of treatment cost, patient access and adherence, patient comorbidities, efficacy of current treatment, clinical guidelines, and provider’s level of experience treating COPD. Further research may help elucidate the relative importance of the factors influencing physicians’ decisions and inform what types of decision-support tools would be most beneficial. Plain Language Summary: Chronic obstructive pulmonary disease (COPD) symptoms can be effectively managed with maintenance therapies, which are treatments that are taken routinely to help improve symptoms. A combination of three different therapies (triple therapy maintenance) has been shown to be more effective than a combination of two different therapies (dual therapy maintenance) in patients with moderate-to-severe COPD. However, maintenance therapies, including triple therapy, are underutilized. This study aimed to explore how physicians make their treatment decisions for patients with COPD, and how combination maintenance therapies are utilized. To do so, we administered a survey to a sample of practicing physicians in the United States. The survey included five clinically based, fictitious profiles, or vignettes, of patients with COPD, with common symptoms and patient characteristics being described. Physicians were then asked to answer questions about what treatment they would prescribe for each patient, and any factors they considered when deciding on a treatment for a patient. We found that cost of treatment and patient access to treatment were the most common barriers that physicians considered when choosing a treatment. Physicians were also more likely to switch a patient’s maintenance inhaler to a triple therapy maintenance inhaler if they considered the patient’s history of new symptoms, patient’s insurance status, and clinical guidelines when making their decisions. Our study shows that there are many complex factors that influence physicians’ decisions when deciding on a treatment for patients with COPD.